272 related articles for article (PubMed ID: 3513779)
1. Effect of the novel orally active angiotensin converting enzyme inhibitor alacepril on cardiovascular system in experimental animals.
Takeyama K; Minato H; Nakatsuji K; Suzuki H; Nose I; Oka M; Hosoki K; Hatano N; Kadokawa T
Arzneimittelforschung; 1986; 36(1):69-73. PubMed ID: 3513779
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
[TBL] [Abstract][Full Text] [Related]
3. Effect of alacepril on renin-angiotensin-aldosterone system and kallikrein-kinin-prostaglandin system in experimental animals.
Hosoki K; Takeyama K; Minato H; Fukuya F; Kawahara S; Kadokawa T
Arzneimittelforschung; 1986; 36(1):77-83. PubMed ID: 3006712
[TBL] [Abstract][Full Text] [Related]
4. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
[TBL] [Abstract][Full Text] [Related]
5. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats.
Nambu K; Matsumoto K; Takeyama K; Hosoki K; Miyazaki H; Hashimoto M
Arzneimittelforschung; 1986; 36(1):47-51. PubMed ID: 3006710
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1507-12. PubMed ID: 3000390
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive mechanism of alacepril: effect on norepinephrine-induced vasoconstrictive response in vitro and in vivo.
Takeyama K; Minato H; Ikeno A; Hosoki K; Kadokawa T
Arzneimittelforschung; 1986; 36(1):74-7. PubMed ID: 3513780
[TBL] [Abstract][Full Text] [Related]
8. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
Matsuno Y; Hori H; Oka M; Nakamura H; Ito T; Kadokawa T
Arzneimittelforschung; 1986; 36(1):62-8. PubMed ID: 3513778
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of the new oral angiotensin converting enzyme inhibitor 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (Alacepril) in essential hypertension.
Mizuno K; Hashimoto S; Kunii N; Tani M; Niimura S; Yabe R; Watari H; Fukuchi S
Res Commun Chem Pathol Pharmacol; 1985 Aug; 49(2):175-87. PubMed ID: 2997886
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of protein conjugate of desacetyl-alacepril and its effect on angiotensin converting enzyme in renal hypertensive rats.
Matsumoto K; Nambu K; Fujii T; Takeyama K; Miyazaki H; Hashimoto M
Arzneimittelforschung; 1986; 36(1):52-4. PubMed ID: 3006711
[TBL] [Abstract][Full Text] [Related]
11. Renal effects of alacepril in essential hypertension.
Tomita K; Nonoguchi H; Terada Y; Marumo F
J Cardiovasc Pharmacol; 1992 Oct; 20(4):520-4. PubMed ID: 1280705
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs.
Hayashi N; Yamamoto S; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):620-5. PubMed ID: 9205775
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic analysis of renal protection by angiotensin converting enzyme inhibitor in Dahl salt-sensitive rats.
Hirawa N; Uehara Y; Kawabata Y; Ohshima N; Ono H; Nagata T; Gomi T; Ikeda T; Goto A; Yagi S
J Hypertens; 1994 Aug; 12(8):909-18. PubMed ID: 7814850
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
Sakatani A; Miyagawa Y; Takemura N
J Vet Cardiol; 2016 Sep; 18(3):248-254. PubMed ID: 27364087
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolism of the novel antihypertensive agent alacepril in rats.
Matsumoto K; Miyazaki H; Fujii T; Yoshida K; Amejima H; Hashimoto M
Arzneimittelforschung; 1986; 36(1):40-6. PubMed ID: 3513776
[TBL] [Abstract][Full Text] [Related]
17. Renal function following sea snake venom (Lapemis hardwicki) administration in dogs treated with sodium bicarbonate solution.
Sakwiwatkul K; Chaiyabutr N; Sitprija V
J Nat Toxins; 2002 May; 11(2):111-21. PubMed ID: 12009111
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic effects of long-term converting-enzyme inhibition in renal hypertensive rats.
Salom MG; Salazar FJ; Fenoy FJ; Pinilla JM; Marín N; Quesada T
Rev Esp Fisiol; 1990 Jun; 46(2):171-6. PubMed ID: 2274701
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive mechanism of alacepril. Effects of its metabolites on the peripheral sympathetic nervous system.
Minato H; Hosoki K; Hayashi K; Sawayama T; Kadokawa T; Hashimoto M
Arzneimittelforschung; 1989 Mar; 39(3):319-24. PubMed ID: 2547387
[TBL] [Abstract][Full Text] [Related]
20. Effect of aprotinin-induced kallikrein inhibition on the cardiovascular and renal action of captopril in diuretic-treated dogs.
Vemulapalli S; Chiu PJ
Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):109-23. PubMed ID: 6191727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
